We further tested GBM patient data from CGGA, and the TUBB6 expression of codel/non-codel (Figure 7A), IDH-mutant/IDH-wildtype (Figure 7B) and the survival probability of primary GBM (Figure 7C) were found to show significant differences (p-value < 0.001), whereas, the survival probability of recurrent GBM was not significantly different, which shows that TUBB6 may be a reliable biomarker for primary GBM prognosis. This evidence concerns the gene TUBB6 and glioblastoma.